I was talking to some folks at a big global pharma last week and I discovered that pharma doesn’t like social networking. (Give me a break – I’m a software security guy, I think about these things in terms of threats to intellectual property and I thought everyone “gets” social networking). If you understand how pharmaceuticals are sold, this is not surprising but it seemed worthwhile to take some time and learn more about the great pharma-social networking divide before diving into a more detailed discussion of why pharmas have a problem with social media (mostly regulation but not just).
For a change – ethics based regulation that differentiates between the medium and the message.
Dr. Jean Ah Kang, works at DDMAC and is in charge of Web 2.0 policy development. She speaks very well at her interview with Mark Senak, a regulatory affairs lawyer ( eyeonfda.com ). Here is the podcast: FDA’s views and ideas about social media and its use in the life sciences industry.